Supernus Pharmaceuticals Raises $42M

Supernus Pharmaceuticals Inc. has raised $42 million by selling its TCD Royalty subsidiary and taking on $15 million in venture debt, the company announced Friday. The sale of TCD Royalty generated $27 million. The company said proceeds will be used to prepare for the commercial launch of its two lead product candidates in epilepsy, and to further the development of its pipeline designed to treat central nervous system diseases. Supernus is based in Rockville, Md.

North AmericaUSBriefs